We plan to incorporate the two risk factors, TP53 and KMT2D, to develop a new prognostic model to identify patients with truly high‐risk PTCL, and to explore new treatment strategies for these patients. The gene discussed is KMT2D; the disease is mature T-cell and NK-cell non-Hodgkin lymphoma.